In conclusion, anti-eIF2B positivity should be suspected when SSc patients are negative for ACA, anti-Topo I, and anti-RNAP3 antibodies but have positive cytoplasmic staining with negative ANA at IIF. This evidence concerns the gene BTG3 and systemic sclerosis.